Palomid 529 (P529) is a novel potent PI3K/Akt/mTOR inhibitor and shows a potent antiproliferative activity in the NCI-60 cell lines panel, with growth inhibitory 50 (GI50) <35 μM. Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. Palomid 529 (P529) inhibited both VEGF-driven (IC50 = 20 nM) and bFGF-driven (IC50 = 30 nM) endothelial cell proliferation and retained the ability to induce endothelial cell apoptosis.
|Preparation method||Human umbilical vascular endothelial cell proliferation.
The proliferation assay was carried out by seeding the HUVECs in 96-well plates at a density of 1,000 per well in complete medium. Following a 24-h plating period, the cells were starved for 24 h in 0.5% serum before being treated with P529 in the presence of 10 ng/mL basic fibroblast growth factor (bFGF) or VEGF in complete medium. After 48 h, cell number was determined using a colorimetric method as described by the supplier (Promega). The results were expressed as the percentage of the maximal bFGF or VEGF response in the absence of P529. Nonproliferating endothelial cells were assayed by growing HUVECs to quiescence in 96-well plates and treating with P529 for 48 h. Initially, 5,000 cells per well were seeded and confluence was achieved the next day. The plates were incubated for another 24 h to ensure growth arrest before treatment with P529. Cell number was determined as outlined above.
|Incubation time||48 h|
|Animal models||U87 glioma xenograft in Four- to 6-wk-old female nude mice|
|Dosages||50 mg and 25mg/kg/2 d, for 1 wk|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.
Lin F et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Dec 15;879(32):3823-31. PMID: 22100549.
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL et al. Endocr Relat Cancer. 2011 Jul 1;18(4):385-400. PMID: 21551258.
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.
Diaz R et al. Br J Cancer. 2009 Mar 24;100(6):932-40. PMID: 19240717.
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.
Xue Q et al. Cancer Res. 2008 Nov 15;68(22):9551-7. PMID: 19010932.
|Related mTOR Products|
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC.
Temsirolimus (CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM.
WYE-125132 is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.
AZD2014 is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.